Am J Transplant, Volume 5, Suppl 3 Archives - Page 102 of 170 - ATC Abstracts

2015 American Transplant Congress
Genetic Diversity Epstein-Barr Virus Latent Gene EBNA-1 Among Transplant Patients and Patients With Infectious Mononucleosis
K. Sullivan,¹ S. Isabel,¹ E. Maria,¹ P. Tara,¹ Y. Simon,¹ K. Nasser,¹ N. Vicky,² A. Upton.¹
¹Department of Infections Diseases, Hospital for Sick Children, Toronto, ON, Canada; ²Transplant Centre, Hospital for Sick Children, Toronto, ON, Canada.
Introduction:-The distribution of Epstein Barr Virus (EBV)-associated pathologies varies worldwide. It is associated with the majority of cases of post-transplant lymphoproliferative disorder (PTLD). The EBNA-1…
2015 American Transplant Congress
Both Preformed and De Novo Cw Donor Specific Antibodies Are Clinically Significant in Renal Transplantation
A. Gueret-Wardle, M. Willicombe, V. Dibbur, P. Brookes, A. McLean, D. Taube.
Imperial College Kidney and Transplant Centre, Imperial College NHS, London, United Kingdom.
Preformed [PF] and de novo [DN] anti-HLA A, B, DR and DQ donor specific antibodies [DSAbs] are associated with poorer allograft outcomes secondary to antibody…
2015 American Transplant Congress
Experimental Study Using Contrast-Enhanced Ultrasonography to Evaluate Rat Chronic Allograft Nephropathy Model and the Relationship Between Hemodynamic Parameters and Renal Allograft Fibrosis
Q. Zhang,¹ Z. Yu,² Y. Xu,¹ S. Zeng,¹ W. Xue,¹ X. Hu.¹
¹Urology Department, Beijing ChaoYang Hospital Capital Medical University, Beijing, China; ²Ultrasound Department, Beijing ChaoYang Hospital Capital Medical University, Beijing, China.
Objectives:To quantitatively analyze the changes of hemodynamic characteristics in renal allograft at different stages of a rat chronic allograft nephropathy [CAN]model and the relationship between…
2015 American Transplant Congress
MHC-Class-II Specific Sensitization in a Non-Human Primate Model of Sensitzation
C. Burghuber,^1,2 J. Kwun,¹ A. Gibby,¹ N. Iwakoshi,¹ S. Knechtle.¹
¹Emory University, Atlanta, GA; ²Medical University Vienna, Vienna, Austria.
[Background] Sensitization before transplantation and de novo alloantibodies affect a significant number of patients awaiting kidney transplantation. The type of anti-HLA antibody varies with subgroups…
2015 American Transplant Congress
The Penalty Faced By Native Americans in Kidney Transplantation: Decreased Access and Reduced Long-Term Survival
S. Stith,¹ F. Barrantes,² K. Piorkowski.¹
¹Department of Economics, University of New Mexico, Albuquerque, NM; ²Renal Medicine Associates/Presbyterian Transplant Center, Albuquerque, NM.
Background: Diabetes and ESRD disproportionately affect NAs (Native Americans), yet waitlisted NAs have lower rates of kidney transplantation than other racial/ethnic groups and worse longer…
2015 American Transplant Congress
Dual Kidney Transplantation – Utilising Marginal Kidneys
T. Rana, E. Ablorsu.
Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom.
Background: With the increasing shortage of donor kidneys a constant review of organ quality and utilisation is required. Getting any positive result from a potential…
2015 American Transplant Congress
Survival Outcomes of Kidney Transplant Recipients from Expanded Criteria Donors: A Systematic Review and Meta-Analysis
A.-H. Querard,^1,2,3 F. Gillaizeau,^1,3 Y. Foucher,^1,3 E. Dantan,³ D. Larmet,¹ M. Lorent,³ L.-M. Pouteau,¹ C. Combescure,⁴ M. Giral.^1,3,5
¹Institute for Transplantation, Urology and Nephrology, CHU Nantes, Inserm U1064, Nantes University, Nantes, France; ²Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France; ³EA 4275 SPHERE-bioStatistics, Pharmacoepidemiology and Human sciEnces REsearch, Nantes University, Nantes, France; ⁴CRC & Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva, Geneva, Switzerland; ⁵LabExTransplantex Nantes, Centre d'Investigation Clinique Biothérapie, Nantes, France.
Background: In 2002, UNOS proposed the use of Expanded Criteria Donors (ECD=brain dead donor > 60 years, or 50-59 years with two criteria: CVA as…
2015 American Transplant Congress
Belatacept Treatment Through Home Infusion as a Safe and Reasonable Alternative to Intitution-Based Treatment: A Retrospective Analysis of Medical Records
T. Kou,¹ A. Deshmukh,¹ J. Preston,¹ A. Gomez,¹ S. Rafanelli,² K. Calderon.¹
¹Bristol-Myers Squibb Company, Princeton, NJ; ²BiologicTx, Totowa, NJ.
Purpose: Belatacept is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant in combination with basiliximab…
2015 American Transplant Congress
Efficacy of Rituximab Sparing Protocol for ABO Incompatible Renal Transplant in Patients With Low Titers
S. Narumi,¹ Y. Watarai,¹ N. Goto,¹ T. Hiramitsu,¹ T. Yamamoto,¹ M. Tsujita,¹ M. Okada,¹ K. Futamura,¹ A. Takeda,² T. Kobayashi.³
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ²Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ³Applied Immunology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
[Introduction]Acute antibody mediated rejection (AMR) has been a major problem in ABO-incompatible kidney transplantation (ABOi-KTx), and currently mycophenolate mofetil and rituximab have been used to…
2015 American Transplant Congress
The Impact of CDC High Risk Donors on Patient and Graft Survival After Liver Transplantation
D. Moonka, A. Yoshida, A. Taylor.
Division of Gastroenterology, Henry Ford Health System, Detroit, MI; Transplant Institute, Henry Ford Health System, Detroit, MI; Department of Public Health Sciences, Henry Ford Health System, Detroit, MI.
We hypothesized that CDC high risk donors (HRD) might be younger than non-HRD and have other characteristics associated with favorable outcomes after liver transplant (LT).…